Definium Therapeutics, Inc. (DFTX) Earnings
Definium Therapeutics, Inc. is expected to report next earnings on November 5, 2026 (in NaN days), with a consensus EPS estimate of $-0.54. DFTX has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise -73.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.54 | $-1.44 | -166.2% | — | — |
| May 7, 2026 | $-0.49 | $-0.71 | -44.3% | — | — |
| Nov 6, 2025 | $-0.52 | $-0.78 | -50.0% | — | — |
| Jul 31, 2025 | $-0.38 | $-0.50 | -31.6% | — | — |
| May 8, 2025 | $-0.36 | $-0.35 | +2.8% | — | — |
| Mar 6, 2025 | $-0.33 | $-0.41 | -24.2% | — | — |
| Nov 7, 2024 | $-0.29 | $-0.27 | +6.9% | — | — |
| Feb 28, 2024 | $-0.48 | $-0.59 | -22.9% | $5M | — |
| Nov 2, 2023 | $-0.65 | $-0.53 | +18.5% | — | — |
| Aug 3, 2023 | $-0.54 | $-0.72 | -33.3% | — | — |
| May 4, 2023 | $-0.41 | $-0.51 | -24.4% | — | — |
| Mar 9, 2023 | $-0.49 | $-0.27 | +44.9% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Clinical Pipeline Progress • In June 2026, Definium reported positive top-line results from eMERGE, the first Phase III trial of lead candidate DT120-ODT for major depressive disorder (MDD). The trial met all primary and key secondary endpoints with high statistical significance, delivering an 8.1-point placebo-adjusted MADRS score improvement at week 6 (p < 0.0001, effect size 0.83), which management states is the largest treatment effect ever reported in a Phase III MDD trial. Efficacy was observed as early as week 1 after a single dose and persisted through week 12, with a favorable tolerability profile. • Enrollment is complete for two Phase III GAD trials (Voyage and Panorama); top-line results from Voyage will be released the week of August 10, 2026, and Panorama results are expected in September 2026. Following protocol-specified blinded sample size re-estimation, both trials now have greater than 99% power to detect a 5-point placebo-adjusted treatment effect. • Enrollment has been initiated for Ascend, the second Phase III MDD trial of DT120-ODT, with top-line data expected in 2027. Preparations are advancing for Haven, the planned Phase III trial for post-traumatic stress disorder (PTSD), expected to initiate in 2027. • The DT402 program for core social communication challenges in Autism Spectrum Disorder (ASD) continues to advance, representing a long-term opportunity in an area with no FDA-approved treatments for this indication. - Regulatory and Pre-Commercial Preparation • The company maintains ongoing constructive dialogue with the FDA, and the FDA's recently finalized guidance aligns with Definium's existing regulatory strategy for DT120-ODT. The company is advancing preparations for a potential New Drug Application (NDA) submission. • A patient and clinician awareness campaign (Wired for Worry) for GAD launched in July 2026, with early positive feedback and strong engagement ahead of GAD trial data readouts. • The commercial team is rapidly expanding across marketing, market access, sales, and operations. Core launch activities including promotional messaging development, payer engagement and value narrative creation, distribution planning, patient support services, and reimbursement pathway development are all advancing. - Financing and Financial Position • In Q2 2026, Definium completed an upsized underwritten public offering that generated $805 million in gross proceeds and $758 million in net proceeds. Based on current operating plans, this capital is sufficient to fund planned operations into 2030, providing financial flexibility to execute on strategic milestones.
Guidance
• No changes to prior clinical trial timelines are announced: top-line results from the Voyage GAD Phase III trial remain on track for release the week of August 10, 2026, with Panorama GAD Phase III results expected in September 2026, Ascend MDD Phase III top-line data expected in 2027, and Haven PTSD Phase III trial initiation expected in 2027. • Management reaffirms that existing capital from the Q2 2026 public offering is sufficient to fund all planned operations into 2030, supporting both clinical development and launch preparation activities. • NDA submission preparation for DT120-ODT is advancing on track alongside ongoing Phase III trials, aligned with current FDA guidance.
Segment performance
Definium Therapeutics is a clinical-stage biotech company, and has no approved commercial products as of Q2 2026, so no product segment revenue is generated. Operating expenses are the only reported financials for the period: Q2 2026 research and development (R&D) expenses were $48.7 million, compared to $29.8 million in Q2 2025. General and administrative (G&A) expenses were $26.4 million in Q2 2026, compared to $11.1 million in the year-ago quarter. Q2 2026 net loss was $159 million, versus a $42.7 million net loss in Q2 2025. The net loss increase included a $86.2 million non-cash expense from marking 2022 USD financing warrants to market, driven by a rise in Definium's share price during the quarter.
Risks & headwinds
• Forward-looking statements (including those regarding clinical trial outcomes, regulatory approval timing, potential launch, and cash runway) are subject to inherent risks, including changes in market conditions, unexpected challenges in research and development, and delays or failures in the regulatory approval process. • Clinical trial success in prior studies does not guarantee positive results in ongoing or future pivotal trials, including the upcoming Voyage and Panorama GAD trials. • Net loss results are vulnerable to quarterly non-cash volatility from fair value adjustments for outstanding 2022 financing warrants, which contributed over half of Q2 2026's net loss.